Press Releases April 30, 2026 04:05 PM

Hawkins, Inc. Expands in Nebraska and Iowa with Acquisition of Aqua-Chem, Inc.

Hawkins, Inc. expands regional presence with Aqua-Chem acquisition to boost commercial pool water treatment business in Nebraska and Iowa.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
HWKN

Hawkins, Inc. has completed the acquisition of Aqua-Chem, Inc., a provider of water treatment products and services for commercial pools in Nebraska and Iowa. This move is aligned with Hawkins' growth strategy in the Water Treatment segment and is expected to enhance opportunities in the commercial pool market through Aqua-Chem's established local presence and loyal customer base.

Hawkins, Inc. Expands in Nebraska and Iowa with Acquisition of Aqua-Chem, Inc.
HWKN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Acquisition broadens Hawkins' footprint in Nebraska and Iowa, enhancing regional market penetration.
  • Aqua-Chem adds complementary products and services focusing on commercial pools, fitting Hawkins' Water Treatment growth strategy.
  • Both companies share strong community ties and customer service cultures, facilitating integration and customer retention.
  • The Water Treatment sector and broader specialty chemicals industry stand to see increased consolidation and competitive positioning through this acquisition.

ROSEVILLE, Minn., April 30, 2026 (GLOBE NEWSWIRE) -- Hawkins, Inc. (Nasdaq: HWKN), a leading water treatment and specialty ingredients company, has completed the acquisition of the assets of Aqua-Chem, Inc. (“Aqua-Chem”).  Aqua-Chem provides water treatment products to commercial pools including chemistry, equipment, and service mainly to Nebraska and Iowa customers.

“The acquisition of Aqua-Chem is important as we continue to execute on our Water Treatment growth strategy and we believe this tuck in acquisition will lead to more opportunities in commercial pools,” said Hawkins Chief Executive Officer, Patrick H. Hawkins. 

Mr. Hawkins continued, “Aqua-Chem has built a strong business and a loyal customer following due to its service and customer intimacy culture, and is well-connected with its local communities, similar to Hawkins.  I would like to welcome the Aqua-Chem team to the Hawkins organization and look forward to our continued growth together.”

About Hawkins, Inc.

Hawkins, Inc. was founded in 1938 and is a leading water treatment and specialty ingredients company that formulates, manufactures, distributes and blends products for its Water Treatment, Food & Health Sciences and Industrial Solutions customers. Headquartered in Roseville, Minnesota, the Company has 66 facilities in 28 states and creates value for its customers through superb customer service and support, quality products and personalized applications. Hawkins, Inc. generated $974 million of revenue in fiscal 2025 and has approximately 1,100 employees. For more information, including registering to receive email alerts, please visit www.hawkinsinc.com/investors.

Contact:               Jeffrey P. Oldenkamp    
                             Executive Vice President and Chief Financial Officer
                             612/331-6910                    
                             ir@hawkinsinc.com


Risks

  • Potential integration challenges could disrupt current customer relationships or operational efficiencies.
  • Economic or regional market fluctuations in Nebraska and Iowa could impact the expected growth benefits from the acquisition.
  • Competition in the water treatment and commercial pool sectors remains intense, which may affect Hawkins' ability to fully leverage the acquisition for growth.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026